Dr. Morteza Naghavi is the founder of SHAPE and executive chairman of the SHAPE Task Force. Dr. Naghavi is an innovative physician researcher and entrepreneur with interests in preventive cardiology, medical technology, and machine learning in healthcare. He graduated as a M.D. from Tehran University in 1995 and was trained under distinguished cardiologists late Dr. Ward Casscells and Dr. James T. Willerson at the Texas Heart Institute where they first discovered and reported that flu vaccine lowers the risk of recurring myocardial infarction. Dr. Naghavi is internationally recognized for his SHAPE initiative. In 2001, pursuant to his research on Vulnerable Plaques and Vulnerable Patient, he founded SHAPE (Society for Heart Attack Prevention and Eradication www.shapesociety.org) a nonprofit organization dedicated to the mission of eradicating heart attacks. In 2006, SHAPE introduced the SHAPE Guidelines which overhauls the existing outdated method of CVD risk assessment in the asymptomatic population. In 2009, SHAPE helped pass Texas legislation HB1290 which became the first heart attack preventive screening law in the US. Dr. Naghavi led several significant publications titled “From Vulnerable Plaque to Vulnerable Patient; A Call for New Definitions and Risk Assessment Strategies. Part I, II, II” which are among the highest cited publications in cardiology. Dr. Naghavi is also the editor of “Asymptomatic Atherosclerosis: Pathophysiology, Detection and Treatment” a comprehensive textbook on Vulnerable Patient. Dr. Naghavi’s research was funded by NIH and NSF. Along with academic activities, Dr. Naghavi is an inventor with over 20 patents and founded multiple companies. One of his companies, Endothelix Inc., www.endothelix.com was selected as a Texas emerging technology and received a $1 million prize. Dr. Naghavi is a venture capitalist and invested in a number of early stage ideas. Physicians and bioengineers with innovative and transformative ideas are welcome to contact Dr. Naghavi mn@vp.org

Detailed Bio